Arcas News
Earlier this month, the ASCO Post featured recent research and analysis from MDoutlook. The article focused on the downstream implications of the FDA revoking the breast cancer indication for bevacizumab on Friday November 18, 2011.
MDoutlook was the first source to report on the global clinical impact of this news through our unique and proprietary oncology intelligence platform now reaching more than 62,000 cancer treaters globally. The research was conducted over a 3-day period directly following the decision with the results from 232 oncologists posted on Wednesday, November 23, 2011 in OBR Daily.
You can read the ASCO Post article here and a link to the original article in OBR is provided here.
For more information on our capabilities to assess, analyze and report on market-moving events in specialty diseases, and on our customized research programs please contact us at info@mdoutlook.com, 888.368.8566 or internationally +1.404.496.4136. A quick overview of our capabilities can be download through this download: MDoutlook capabilities.
January 23rd, 2012
On behalf of the Arcas Group team, we wish you an enjoyable and relaxing holiday season!
In preparation for a prosperous 2012, please accept our gift of complimentary MDOUTLOOK® Analysis Reports.
MDOUTLOOK, our exclusive web-based platform, provides the marketplace insight critical to reaching your commercialization goals. Our customized approach engages over 60,000 multi-disciplinary specialists active in oncology care worldwide.
Complimentary 2011 Analysis Reports - immediately available for download:
* Global Clinical Impact of Bevacizumab Revocation in metastatic Breast Cancer
* Recent Developments in the Treatment of Myelofibrosis
* New Clinical Data in Pancreatic Neuroendocrine Tumors
* ASCO 2011: Immediate Impact on Clinical Practice in NSCLC
* ASCO 2011: Immediate Impact on Clinical Practice in Melanoma
* ASCO 2011: Immediate Impact on Clinical Practice in Gastrointestinal Cancer
Explore MDOutlook to discover the advantage of total oncology intelligence. You can preview the MDOUTLOOK advantage here or contact us at info@mdoutlook.com to discuss your intelligence needs.
With best wishes for 2012!
The Arcas Group and MDOUTLOOK Teams
December 19th, 2011
Through our disease intelligence service, MDoutlook, Arcas has have provided insight and support for several news items since the summer:
* An article was published in the journal Value-Based Cancer Care in August 2011 about the cost implications for novel therapies in the treatment of non-small cell lung cancer (NSCLC). MDoutlook provided key insight on how the US and global community of medical oncologists will shift their management of NSCLC based on new information presented at ASCO 2011.(Article VBCC 08-2011)
* This month OBR published an article featuring immediate market insight delivered by MDoutlook to gauge the clinical impact of the recent FDA decision to revoke marketing authorization of bevacizumab (Avastin®) in HER-2 negative metastatic Breast Cancer. The article can be read here.
MDOUTLOOK, the global oncology intelligence platform, provides crucial insight into the dynamic role of clinicians involved in treating today’s oncology patient. You can read more about MDoutlook here. If you would like to talk to us or schedule a demo, please contact us at info@thearcasgroup.com.
November 23rd, 2011
We are very pleased to welcome Allison Easley to the leadership of The Arcas Group as Director, Account Services. She joins with more than 15 years of experience in servicing the pharmaceutical and biotech industry, in the United States, Europe and other regions.
Allison has used her expertise, insight and deep understanding of all Oncology/hematology tumor types in addition to respiratory medicine, immunology, critical care, and urology to design strategies and activities and meet brand objectives. She has built and utilized a variety of communication, research & media platforms for activities supporting a variety of functions at life science companies, including Commercialization Strategy, Strategic Marketing, Advocacy development, Consulting Activities, Publication Planning, Tactical Planning, Market Research, Medical Education, and Medical Communications.
“I am excited to have Allison join our team. Having worked with her in earlier stages of her career, I continue to be impressed with her high levels of energy, great insight and her dedication to consistently exceed client expectations. She is a great asset to our company and will be instrumental in expanding our relationship with our clients,” says Jan Heybroek, President of The Arcas Group.
“Arcas continues to multiply its revenue and client base through our unwavering commitment to exceed client expectations, which is highlighted by our extremely high retention client rate of 94% and the growth of business per client. Our staff rates amongst the very best in the industry, and it is a real pleasure and privilege to lead the team on the growth path we have followed from the company’s inception. This year alone we have signed on 10 new clients to our roster and have grown the MDOUTLOOK network of cancer physicians to more than 53,000 worldwide.”
November 23rd, 2011
MDOUTLOOK, the global oncology intelligence initiative powered by The Arcas Group, announced results from its 4th Annual Quick Poll research launched immediately following this month’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. These Quick Polls expand on previous Quick Polls carried out after the past 3 ASCO annual meetings, and other meetings such American Society of Hematology (ASH) and San Antonio Breast Cancer Symposium (SABCS).
Within one week, 515 cancer treaters in 38 countries responded to 4 individual Quick Polls on melanoma, non-small cell lung cancer (NSCLC), gastrointestinal (GI) cancers and genitourinary (GU) cancers. This is the first market feedback available post-ASCO. Highlights from this significant research study include:
- News from ASCO impacts the entire oncology community. A wide variety of sources are used to learn about the important news from this conference.
- The novel targeted agents vemurafenib and ipilimumab will become the standards of care for malignant melanoma. More than half of all patients with malignant melanoma are expected to receive one if not both of these agents.
- Physicians are excited about the identification of specific NSCLC patient subpopulations who will respond to crizotinib, erlotinib, or MetMab.
- Following their recent regulatory approvals, worldwide use of everolimus and sunitinib for pancreatic neuroendocrine tumors (PNET) will greatly increase.
- There is not a consistent approach to the continued use of anti-angiogenic therapy after progression in stage IV colorectal cancer. Physicians are eagerly awaiting the results of definitive clinical trials which are due in the near future.
- Axitinib is expected to be the most common 2nd line therapy following sunitinib for metastatic renal cell carcinoma (mRCC). However, clinicians use a personalized approach in this setting.
- The clinical landscape for prostate cancer is undergoing a dramatic shift due to a number of new therapeutics; some of which have been recently approved and others still under clinical development.
- The primary clinical trial endpoint reported influences the integration of research into clinical practice.
Members of the MDOUTLOOK Strategy Council reflected that these results “validate the expected change in physician decision-making” and that “it will be interesting to follow-up on a regular basis to track these changes.”
Jan Heybroek, President of The Arcas Group, LLC, which powers MDOUTLOOK commented: “These Quick Polls perfectly demonstrate the ability of MDOUTLOOK to rapidly and in a targeted manner capture the views of validated cancer physicians around the world, and turn this into actionable intelligence.”
Full copies of the 4th Annual MDOUTLOOK Quick Polls from ASCO are available upon request.
About MDOUTLOOK®
MDOUTLOOK was developed with a singular focus: improved understanding of complex diseases leading to better patient care. Over 52,000 medical oncology professionals have opted into a network of their peers through the MDOUTLOOK online platform to share information such as preferred treatment regimens for complex diseases and de-identified patient logs, as well as the factors that play a part in their clinical decision-making.
Physician members of MDOUTLOOK benefit by having access to data on how other clinicians manage difficult cases and how they are adapting to changes in the industry, ranging from the introduction of new drugs or treatment modalities, to the rising costs of certain treatments. For many physicians, MDOUTLOOK also serves as a patient registry.
MDOUTLOOK is guided by a Strategy Council of globally recognized experts: Alexander Eggermont, MD, PhD; Keith Flaherty, MD; William Gradishar, MD; Axel Hauschild, MD; Peter Heald, MD; John Kirkwood, MD; Sagar Lonial, MD; Lauren Pinter-Brown, MD; Joyce O’Shaughnessy, MD; Nicholas Thatcher, MD; and Alan Venook, MD.
MDOUTLOOK delivers life-sciences clients real-time ThoughtLeader and clinician-driven analysis, intelligence and insight into oncology clinical practice (www.thearcasgroup.com/mdoutlook).
About The Arcas Group
The Arcas Group is a strategic life sciences marketing organization with a singular focus: Supporting the commercial success of its clients in the continuum of life sciences marketing – from marketing intelligence to strategy development and implementation – through enhanced connectivity with ThoughtLeaders and Clinicians. MDOUTLOOK is a key offering that is highly valued by its rapidly expanding base of clients.
For more information, please visit The Arcas Group’s website at www.thearcasgroup.com.
CONTACT: Jan A. Heybroek, President, jheybroek@thearcasgroup.com, +1-404-496-4136
July 13th, 2011
MDOUTLOOK and Oncology Business Review, two leading organizations in oncology business intelligence, are hosting a complimentary program exclusively for senior decision-makers in oncology commercialization. You are invited to attend ‘On-College: Insights and Strategies for Fostering Pharma-Physician Relationships in Today’s Dynamic Oncology Marketplace‘.
This inaugural event will take place during ASCO 2011 on Monday, June 6 from 6-8pm at the InterContinental Chicago. This program is by invitation only and intended for commercial oncology professionals interested in improving the value proposition from manufacturers to other cancer stakeholders.
Co-Chairs
Howard S. Hochster, M.D., Associate Director, Yale Cancer Center and Professor of Medicine, Yale School of Medicine
Michael G. King, Jr., Senior Vice President of Corporate Development and Communication, ZIOPHARM Oncology, Inc.
Moderator
Don Sharpe, Publisher, OBR
Panel Discussion
Jan A. Heybroek, President, The Arcas Group & MDOUTLOOK
Howard S. Hochster, M.D., Associate Director, Yale Cancer Center and Professor of Medicine, Yale School of Medicine
Don Sharpe, Publisher, OBR
Michael G. King, Jr., Senior Vice President of Corporate Development and Communication, ZIOPHARM Oncology, Inc.
Please download our printable invitation and email us at event@mdoutlook.com if you or any of your colleagues would like to attend.
We look forward to seeing you in Chicago!
Kind regards,
Jan Heybroek
President, The Arcas Group & MDOUTLOOK
May 27th, 2011
March 18th, 2011
A number of current events are going to have a significant impact on the treatment of metastatic breast cancer in Europe: the EMA has recently reduced the marketing approval for bevacizumab and new positive data from the EMBRACE trial (eribulin in the recurrent setting) were made available.
MDoutlook launched a Quick Poll™ among its 12,000+ European medical oncology members to determine how these events are and will be affecting clinical practice. Responses from 13 countries (>60% of responses were from the 5-EU) show the following:
• Initial uptake in usage of eribulin will be stronger in later lines of treatment, although a majority of oncologists will begin using eribulin in the 2nd line for some of their metastatic breast cancer patients (see figure below)
• It is widely believed that eribulin will soon prove to be effective as an initial treatment for metastatic breast cancer with less acceptance as a neoadjuvant or adjuvant agent
• Significant reductions in the use of bevacizumab + docetaxel in metastatic breast cancer have recently been made by oncologists; further reductions in the use of this combination will occur due to the EMA’s decision
• The use of bevacizumab + paclitaxel, which was unaffected by the recent EMA decision, has had and will have only some minor reductions in usage for metastatic breast cancer. The use of bevacizumab in other tumor types are also relatively unaffected
To download a free copy of this MDoutlook report (in .pdf format), click here Changing European Paradigms for the Treatment of Metastatic Breast Cancer.
MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader-composed Strategy Councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 51,000+ cancer treaters and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians
For more information about MDoutlook or to receive PowerPoint slides of this report, please email info@MDoutlook.com or call +1.404.496.4136.
March 18th, 2011
February 15th, 2011
Last Thursday, two articles in the New England Journal of Medicine described exciting results with sunitinib (Sutent®) and everolimus (Afinitor®) from phase III clinical trials in pancreatic neuroendocrine tumors (PNET). To gauge the immediate impact these reports could have with the global oncology community, MDoutlook launched a global Quick Poll™ of its medical oncology members. Based on the initial results collected over the weekend:
• While 40-50% of oncologists are already using sunitinib or everolimus for the treatment of some of their patients with PNET, over 80% plan on using them in 2011
• The amount of patients with PNET who will receive sunitinib or everolimus for treatment in 2011 is predicted to expand by 2.5-3.0 fold over current levels (see figure below)
• Three quarters of oncologists expect their PNET patients will stay on extended therapy with these agents regardless of the potential for serious side effects
• Usage of these agents in PNET will have little to no effect on their use in metastatic renal cell carcinoma (where both currently have FDA-approval).
MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader composed-strategy councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 50,000 oncologists and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians
For more information about MDoutlook or to receive a final copy of this report when it is available next week, please email info@mdoutlook.com or call +1.404.496.4136.
February 15th, 2011
Recently, MDoutlook was featured in two articles that will help our clients and contacts with your marketing planning and tactics in 2011. We gladly share these with you.
• MDoutlook oncology insight and market adoption trends are featured in this month’s Oncology Business Review (OBR). More than 500 oncologists responded to exclusive Quick Polls fielded immediately after the December American Society of Hematology meeting (ASH) and San Antonio Breast Cancer Symposium (SABCS). We are offering you complimentary access to the full report here.
• Pharmaceutical Executive has interviewed MDoutlook to provide perspectives on 2011 trends in Pharma, with a focus on oncology. You can read the article here.
MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader composed-strategy councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 50,000 oncologists and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians
For more information please email info@MDoutlook.com or call +1.404.496.4136.
January 24th, 2011
FOR IMMEDIATE RELEASE
CONTACT:
Jan A. Heybroek – President, The Arcas Group, LLC
jheybroek[at]thearcasgroup.com
+1.404.496.4136
MDOUTLOOK® Quick Polls from the Major Oncology/Hematology Meetings ASH and SABCS: First Report from Cancer Treaters on Clinical Impact of New Cancer Developments
Atlanta, GA, United States – December 21, 2010
MDOUTLOOK®, the oncology intelligence initiative powered by The Arcas Group, today announced results from its series of immediate Quick Poll research launched following major oncology and hematology market moving events. These Quick Polls examined the potential clinical impacts from the American Society of Hematology (ASH) annual meeting in Orlando and the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). This effort expands on previous Quick Poll research carried out after the American Society of Clinical Oncology (ASCO) annual meetings in 2009 and 2010.
Within one week, 506 cancer treaters from over 30 countries responded to the Quick Poll research following the ASH and SABCS meetings, making this the first market feedback available post-ASH and post-SABCS. Some of the highlights from this research include:
• Decisions concerning the use of drugs are primarily made independently of any indications / approvals in different malignancies, even if it is in a related tumor type.
• Maintenance therapy with lenalidomide is seen as a highly important advance in the management of multiple myeloma. It is expected that half of all patients with multiple myeloma will receive this therapeutic approach in 2011.
• There appears to be a new standard of care for mantle cell lymphomas: alternating cycles of CHOP and DHAP (both with rituximab), followed by high dose ARA-C and autologous stem cell transplantation.
• Oncologists / Hematologists are not differentiating primary from secondary AML in their outlook for new therapeutics.
• New data showing a lack of association between CYP2D6 phenotype and tamoxifen responsiveness will cut in half the amount of CYP2D6 genotyping being performed in postmenopausal women with HR+ breast cancer from 11 to 5%.
• Dual targeting the HER2 receptor is a very important clinical advance for HER2+ breast cancer. The use of this strategy in appropriate breast cancer subtypes with currently available therapeutics is expected to double in 2011.
Members of the MDOUTLOOK Strategy Council reflected that these results “show the quick and strong uptake of new developments presented into physician decision-making on a global scale” and that “it will be of value to follow-up on a regular basis to track these changes.”
Jan Heybroek, President of The Arcas Group, LLC, which powers MDOUTLOOK commented: “These Quick Polls perfectly demonstrate the ability of MDOUTLOOK to quickly and in a targeted manner capture the views of validated cancer physicians around the world, and turn this into actionable intelligence.”
These Quick Polls are the seventh in a series of Quick Polls following major oncology conferences. Full reports of the 2010 Quick Polls from ASH, SABCS and ASCO are available upon request.
About MDOUTLOOK®
MDOUTLOOK has been developed with a singular focus: improved understanding of complex diseases leading to better patient care. Over 47,000 cancer treating physicians have opted into a network of their peers through the MDOUTLOOK Internet-based system to share information such as preferred treatment regimens for complex diseases and de-identified patient logs, as well as the factors that play a part in their clinical decision-making.
Physician members of MDOUTLOOK benefit by having access to data on how other clinicians in practice treat difficult cases and how they are adapting to changes in the industry, everything from the introduction of new drugs or treatment modalities, to the rising costs of certain treatments. For many physicians, MDOUTLOOK also serves as a patient registry.
MDOUTLOOK is guided a Strategy Council of globally recognized experts: Chandra Belani, MD; Alexander Eggermont, MD, PhD; Keith Flaherty, MD; William Gradishar, MD; Axel Hauschild, MD; Peter Heald, MD; John Kirkwood, MD; Sagar Lonial, MD; Lauren Pinter-Brown, MD; Giorgio Scagliotti, MD, PhD; Joyce O’Shaughnessy, MD, and Nicholas Thatcher, MD.
MDOUTLOOK delivers life-sciences clients real-time ThoughtLeader and clinician-driven analysis, intelligence and insight into oncology clinical practice (www.thearcasgroup.com/mdoutlook).
About The Arcas Group
The Arcas Group is a strategic life sciences marketing organization with a singular focus: Supporting the commercial success of our clients in the continuum of life sciences marketing – from marketing intelligence to strategy development and implementation – through enhanced connectivity with ThoughtLeaders and Clinicians. MDOUTLOOK is a key offering that is highly valued by its rapidly expanding base of clients.
For more information, please visit The Arcas Group’s website at www.thearcasgroup.com.
Copy of the release can be found here.
December 21st, 2010
Previous Posts
